Stay updated on Lenvatinib and Pembrolizumab in DTC Clinical Trial
Sign up to get notified when there's something new on the Lenvatinib and Pembrolizumab in DTC Clinical Trial page.

Latest updates to the Lenvatinib and Pembrolizumab in DTC Clinical Trial page
- Check5 days agoNo Change Detected
- Check13 days agoChange DetectedAdded a note clarifying that publications are automatically filled from PubMed and may not be about the study. Updated the revision label to v3.3.2, replacing the previous v3.2.0.SummaryDifference0.1%

- Check20 days agoChange DetectedThe government funding lapse notice about NIH operations, previously displayed on the page, has been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check34 days agoChange DetectedTwo screenshots show only minor layout and timestamp differences. No substantive content changes to core study details (objectives, eligibility criteria, or outcomes) are visible.SummaryDifference0.3%

- Check63 days agoChange DetectedSummary of changes: Deleted the GI/RDI Genetic and Rare Diseases resource for Differentiated thyroid carcinoma and added a government-operating-status notice with a v3.2.0 update.SummaryDifference2%

- Check70 days agoChange DetectedThe page update adds the new version tag v3.1.0 and removes the old v3.0.2 tag, signaling a software version upgrade.SummaryDifference0.1%

- Check84 days agoChange DetectedPage version updated from v3.0.1 to v3.0.2; the 'Back to Top' control was removed. No other core content, pricing, or availability changes were detected.SummaryDifference0.1%

Stay in the know with updates to Lenvatinib and Pembrolizumab in DTC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lenvatinib and Pembrolizumab in DTC Clinical Trial page.